# Halozyme Therapeutics (HALO) — Overview

HALO · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/halo

## Price

Last close $121.51 on Oct 15, 2026. 52-week range $61.63 – $121.51.

## Company profile

Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.

## Financials

| Metric | Value |
| --- | --- |
| Revenue (trailing twelve months) | $1.7B |
| Revenue (quarter) | $481.0M |
| Revenue growth (year over year) | 47.67% |
| Gross profit (trailing twelve months) | $1.4B |
| Gross margin | 82.42% |
| Net income (trailing twelve months) | $413.6M |
| Net income (quarter) | $229.9M |
| Net income growth (year over year) | 39.21% |
| Net margin | 24.86% |
| Return on equity | 173.67% |
| EPS (trailing twelve months) | $3.55 |
| Book value per share | $1.26 |
| P/E (trailing twelve months) | 33.3 |
| Price to book | 96.1 |
| Debt to assets | 94.43% |
| Payout ratio | 0.00% |
| Dividend yield | 0.00% |

## Frequently Asked Questions

### Is Halozyme Therapeutics (HALO) profitable?

Yes. Halozyme Therapeutics earned $413.6M in net income over the trailing twelve months, a net margin of 24.86%.

### How much revenue does Halozyme Therapeutics (HALO) make?

Halozyme Therapeutics generated $1.7B in revenue over the trailing twelve months, up 47.67% year over year.

### What is HALO's P/E ratio?

Halozyme Therapeutics trades at 33.3 times trailing twelve-month earnings, on an EPS of $3.55.

### How do I buy stock in Halozyme Therapeutics (HALO)?

HALO trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at [Light Horse Dashboard](https://portal.lighthorse.io), the trading API, or an [AI agent connected over MCP](/instructions/ai/claude). The trade panel on this page places the order once you are signed in.

---

Quotes and charts are not real-time and must not be relied on for trade decisions or valuation.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).